Drug intelligence / Profile preview

Liugan Shuangjie Heji

Development stage: Phase 2
Lead developer: Beijing University of Chinese Medicine East Hospital
Administration: Oral

Overview

Liugan Shuangjie Heji is a traditional Chinese medicine used for treating influenza. It is administered orally, typically 4 times a day at a dosage of 100 ml each time (equivalent to two doses per day) for a course of five days. The medication appears to be part of a "reconciling exterior and interior therapy" approach in Chinese medicine.

Other names: liu gan shuang jie

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)CASP8 (Caspase-8)CASP9 (Caspase-9)

Beyond the preview

Go deeper on Liugan Shuangjie Heji.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liugan Shuangjie Heji.

Explore the full profile